When stock price has continually depreciated for three months, it's understood many investors have self injected FUD. In a matter of fact, nwbio is still worthy of about 1 billion in MC which by and in itself is a very bullish sign.
Because nwbo is an otc stock without serious money support, and it's in effect a retail stock; CEO Linda is hated by pretty much everybody, longs hate her for never ever delivering on her own schedule; shorts hate her for never ever giving in/up, so ambitious, go big or go home mantra; the sideliners hate her for suspicious of her double dealing, enriching herself but not common investors ...
But the market still believes nwbio's product DCVax-L will be ultimately a success regardless, and the market is right.
Anyone has a brain and has spent one half day of time doing own DD would realize DCVax-L trial data would be at least beating Optune's, and at least the primary endpoint would be significant. There may be ups and downs in the road of approval, but we will be definitely there.
In conclusion the data at worst would be controversial but it will demonstrate efficacy. With its pristine safety, no RAs would deny its approval.
The above is the worst case scenario for me, and I think the market agrees with me.
on the other hand, the serious money now waiting for data and uplifting to buy, Linda and her gang waiting for rewarding themselves with options at lowest price possible, and pretty much everyone except fully committed retails like myself, ... all want the share price as low as possible.
So it's clear the recent price is a strong-buy price, if not the lowest before major climb embarks.
